February 14, 2018 / 12:26 PM / 3 months ago

BRIEF-Intercept Pharmaceuticals Reports Q4 Net Loss Per Common & Potential Common Share $4.43

Feb 14 (Reuters) - Intercept Pharmaceuticals Inc:

* INTERCEPT PHARMACEUTICALS REPORTS FULL YEAR AND FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

* REGENERATE TRIAL IN NASH FIBROSIS ON TRACK TO REPORT DATA IN 1H19

* PROJECTS NON-GAAP ADJUSTED OPERATING EXPENSES OF $390 MILLION TO $410 MILLION FOR FISCAL YEAR ENDING DEC 31, 2018

* QTRLY NET LOSS PER COMMON AND POTENTIAL COMMON SHARE $4.43

* Q4 EARNINGS PER SHARE VIEW $-3.55, REVENUE VIEW $39.0 MILLION — THOMSON REUTERS I/B/E/S

* Q4 REVENUE $37.7 MILLION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below